We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZENA:NASDAQZenaTech, Inc. Analysis

Data as of 2026-05-28 - not real-time

$1.43

Latest Price

8/10Risk

Risk Level: High

Executive Summary

ZenaTech’s stock is trading well below its 52‑week high, with price hovering near recent support levels. Technical indicators show a bearish alignment: the short‑term moving average sits beneath the mid‑term average, and the MACD line is under its signal. Momentum appears weakened as the RSI has slipped into a low range, hinting at oversold conditions. Volume has been rising, suggesting increased market participation despite the downtrend. The company’s balance sheet is strained, featuring a debt load that far exceeds its cash holdings and persistent negative cash flows. Nonetheless, recent press releases highlight new revenue‑generating contracts and a rapidly growing DaaS segment delivering substantial revenue in its first full year.
The sector’s average PE is dramatically higher than ZenaTech’s negative earnings, underscoring the stock’s relative cheapness. However, extreme price volatility and a beta well above one amplify market risk. The “Extreme Greed” sentiment index reflects heightened speculative interest, which could fuel short‑term price swings. With no dividend and a negative book value per share, income‑based valuation metrics are largely irrelevant. Given the blend of upside potential from emerging product lines and the substantial execution risk, the investment case leans toward a speculative growth play. Investors should weigh the bearish technical backdrop against the company’s strategic expansion before deciding on exposure.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish technical indicators
  • High volatility and beta
  • Negative cash flow and debt load

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential revenue expansion
  • Increasing trading volume
  • Continued earnings losses

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Significant upside potential
  • Emerging product lines
  • Undervalued relative to sector peers

Key Metrics & Analysis

Financial Health

Revenue Growth670.80%
P/E Ratio-5.8
ROE-100.73%
ROA-23.55%
Debt/Equity31.57
P/B Ratio-7.1
Op. Cash Flow$-35461668
Free Cash Flow$-42942128
Industry P/E40.4

Technical Analysis

TrendBearish
RSI35.3
Support$1.15
Resistance$2.59
MA 20$1.83
MA 50$2.05
MA 200$3.54
MACDBearish
VolumeIncreasing
Fear & Greed Index91.48

Valuation

Target Price$6.85
Upside/Downside379.26%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta2.47
Volatility130.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.